Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience

Eşkazan, Ahmet Emre; Özmen, Deniz; Öztaş, Mert; Bektaş, Fatih; Bayraktar, Eşref Alperen; Sadri, Sevil; Keskin, Dilek; Yurttaş, Nurgül Özgür; Elverdi, Tuğrul; Salihoğlu, Ayşe; Ar, Muhlis Cem; Öngören, Şeniz; Başlar, Zafer; Aydın, Yıldız; Soysal, Teoman

doi:10.1016/j.clml.2021.04.005

Cited by 5 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MD Anderson Cancer Center (MDACC) group [ 27 ] conducted the first extended analysis on efficacy and safety of imatinib in older patients, showing similar cytogenetic response rates compared to younger CP patients. To follow, European experiences, in clinical trials and real-life settings [ 28 , 29 , 30 , 32 ], confirmed the absence of significant differences between elderly and younger patients treated with frontline imatinib as to cytogenetic/molecular responses and long-term outcomes. More recently, a similar efficacy was described for 2G-TKIs both in elderly and younger patients [ 30 , 31 ].…”

Section: Baseline Prognostic Factorsmentioning

confidence: 93%

“…In particular, the elderly experienced more toxicities with interferon-alpha (IFN-α) therapy, resulting in poorer treatment tolerance and inadequate drug delivery and significantly higher rates of transplantation-related mortality regardless of the underlying disease [ 24 , 25 , 26 ]. Many studies revealed that the negative impact of older age on response, and, partially, survival rates were nearly eliminated with the introduction of TKIs [ 27 , 28 , 29 , 30 , 31 ]. The MD Anderson Cancer Center (MDACC) group [ 27 ] conducted the first extended analysis on efficacy and safety of imatinib in older patients, showing similar cytogenetic response rates compared to younger CP patients.…”

Section: Baseline Prognostic Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights

Iezza

Cortesi

Ottaviani

et al. 2023

Cells

View full text Add to dashboard Cite

The introduction of tyrosine kinase inhibitors (TKIs) has changed the treatment paradigm of chronic myeloid leukemia (CML), leading to a dramatic improvement of the outcome of CML patients, who now have a nearly normal life expectancy and, in some selected cases, the possibility of aiming for the more ambitious goal of treatment-free remission (TFR). However, the minority of patients who fail treatment and progress from chronic phase (CP) to accelerated phase (AP) and blast phase (BP) still have a relatively poor prognosis. The identification of predictive elements enabling a prompt recognition of patients at higher risk of progression still remains among the priorities in the field of CML management. Currently, the baseline risk is assessed using simple clinical and hematologic parameters, other than evaluating the presence of additional chromosomal abnormalities (ACAs), especially those at “high-risk”. Beyond the onset, a re-evaluation of the risk status is mandatory, monitoring the response to TKI treatment. Moreover, novel critical insights are emerging into the role of genomic factors, present at diagnosis or evolving on therapy. This review presents the current knowledge regarding prognostic factors in CML and their potential role for an improved risk classification and a subsequent enhancement of therapeutic decisions and disease management.

show abstract